William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Phipps has given his Buy rating due to a combination of factors including the promising potential of Upstream Bio’s TSLP receptor antibody, verekitug, in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The upcoming Phase II study results of verekitug, expected in the third quarter, are anticipated to provide significant insights into its efficacy and safety profile, which could position it favorably in the CRSwNP treatment landscape.
Additionally, the involvement of esteemed experts such as Joseph Han, M.D., and the strategic leadership of Upstream Bio’s management team, including CEO Rand Sutherland and Chief Medical Officer Aaron Deykin, further bolster confidence in the company’s direction and potential success. These elements combined suggest a strong outlook for Upstream Bio, justifying the Buy rating.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $75.00 price target.